Cellectis Reports Preliminary Clinical Data for UCART22 and UCART123 Therapies

Cellectis has released encouraging preliminary clinical data for two of its gene-edited T-cell therapy candidates, UCART22 and UCART123. The company reported positive findings in the treatment of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), presented at the American Society of Hematology (ASH) annual meeting.

In the BALLI-01 study, UCART22 demonstrated anti-tumor activity in 60% of patients treated at dose level 3 (DL3). Among these patients, one achieved a durable complete response with minimal residual disease (MRD) negativity, sustained for over six months.

For the AMELI-01 study, UCART123 treatment led to a meaningful response in two out of eight patients (25%) at dose level 2 (DL2) with FCA conditioning. One patient achieved a sustained MRD-negative complete response lasting over 12 months.

Cellectis is continuing to evaluate both therapies and has begun enrolling patients in the BALLI-01 study with an in-house manufactured product candidate. Patients are now being enrolled for a two-dose regimen in the AMELI-01 study.